title: Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment.
authors.forename: Quan V
authors.initials: QV
authors.lastname: Hoang
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Kiernan
authors.forename: Felix Y
authors.initials: FY
authors.lastname: Chau
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Shapiro
authors.forename: Michael P
authors.initials: MP
authors.lastname: Blair
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005451:Fluorescein Angiography; D005865:Gestational Age; D006801:Humans; D052577:Infant, Extremely Low Birth Weight; D007231:Infant, Newborn; D007267:Injections; D017075:Laser Coagulation; D008297:Male; D012008:Recurrence; D012178:Retinopathy of Prematurity / Q000175:diagnosis* / Q000209:etiology* / Q000601:surgery; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab